[go: up one dir, main page]

US20080096963A1 - Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings - Google Patents

Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings Download PDF

Info

Publication number
US20080096963A1
US20080096963A1 US11/572,437 US57243707A US2008096963A1 US 20080096963 A1 US20080096963 A1 US 20080096963A1 US 57243707 A US57243707 A US 57243707A US 2008096963 A1 US2008096963 A1 US 2008096963A1
Authority
US
United States
Prior art keywords
acid
cis
fatty acid
hymenoptera
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/572,437
Inventor
Theirry Jean
Fabrice Balavoine
Mark Crawford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cerep SA
Original Assignee
Cerep SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cerep SA filed Critical Cerep SA
Publication of US20080096963A1 publication Critical patent/US20080096963A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • the present invention relates to the use of a fatty acid for the preparation of a topical composition for allaying inflammatory reactions due to hymenoptera stings.
  • insects that secrete substances harmful to humans are rather numerous in our part of the world. Between wasps, hornets, bumblebees, ants and honeybees, the risks of being stung are not insignificant. These insects are called hymenoptera. Their sting can cause local or generalized non-allergic reactions as well as local or generalized allergic reactions.
  • a typical reaction to a hymenoptera sting consists of immediate pain combined with redness, itching and edema in an area several centimeters in diameter. The progression of the reaction is variable. The reaction can last a few hours (three on average) and generally does not last more than one day. Particular types of reactions do exist, however. Stings that lead to non-allergic reactions at specific sites can have dramatic consequences. Stings in the oral cavity, in particular at the back of the throat, can lead to respiratory disorders due to local edema. Finally, stings to the cornea of the eye can cause immediate complications such as an ocular abscess or perforation of the globe. Certain complications may appear later, including cataracts or glaucoma.
  • Allergic reactions concern roughly 1% of the population. They can be local, regional, generalized or delayed. They are generally categorized according to severity: local reaction (broader than the normal reaction but limited to a limb), regional reaction (reaction that reaches the joints of the stung limb), generalized reaction (distal skin, respiratory symptoms, Quincke's edema, asthma, digestive symptoms, palpitations), and anaphylactic shock (drop in blood pressure in addition to the symptoms described, spontaneously fatal).
  • the hymenoptera include a number of species including bees, wasps, hornets and ants. Although most hymenoptera stings cause only moderate pain and a limited, temporary reaction, they may be dangerous, even fatal, if multiple stings occur, if they occur in the mouth, in the throat, or to the eye, or if the stung subject has an allergic reaction.
  • the stung subject initially feels a more or less sharp pain depending on the type of insect and the quantity of venom injected. The skin around the sting becomes red and swollen. The subject feels itching that is more or less intense.
  • insect venom in particular bee venom, is a complex substance comprised of a large number of active compounds including histamine, melittin, hyaluronidase and phospholipase A. Sensitivity to these venom proteins may explain some of the reactions described above.
  • these fatty acids in particular C12-C24 acids, considerably reduce the inflammatory reaction that follows a hymenoptera sting.
  • the present invention relates to the use of a fatty acid for preparing a topical or injectable composition for allaying inflammatory reactions due to hymenoptera stings.
  • the fatty acids used in the present invention are preferably natural fatty acids, i.e., capable of being obtained from natural product such as oils, but also synthetic fatty acids that are identical to or are different from natural fatty acids.
  • suitable fatty acids may be saturated or unsaturated fatty acids.
  • the salts or the pharmaceutically acceptable derivatives of these fatty acids that are also fatty acids may also be used.
  • fatty acids used within the framework of the present invention the following may be cited in particular: C12 to C24 acids, lauric (n-dodecanoic) acid, myristic (n-tetradecanoic) acid, palmitic (n-hexadecanoic) acid, stearic (n-octadecanoic) acid, arachidic (n-eicosanoic) acid, behenic (n-docosanoic) acid, lignoceric (n-tetracosanoic) acid, palmitoleic (cis- ⁇ 9 -hexadecenoic) acid, oleic (cis- ⁇ 9 -octadecenoic) acid, linoleic (cis,cis- ⁇ 9 -, ⁇ 12 -octadecadienoic) acid, linolenic (all-cis- ⁇ 9 -, ⁇ 12 -, ⁇ 15 -octade
  • Polyunsaturated fatty acids are preferred, and linoleic acid and oleic acid are particularly active in the use according to the invention.
  • the fatty acids were tested in vitro for their capacity to inhibit the activity of certain pro-inflammatory components of bee venom, and tested in vivo in rat in models of bee venom induced edemas.
  • composition to which the invention relates may also include other active ingredients, notably an anesthetic and/or an antibiotic and/or an anti-allergic or anti-inflammatory substance.
  • the fatty acids can be formulated in any form suitable for topical administration, in combination with suitable excipients, to allow administration of a dose of 0.01 mg to 50 mg per venomous hymenoptera sting.
  • the dose may vary according to the quantity of venom absorbed, the number of stings or the type of insect.
  • galenical formulations which may be suitable for implementing the invention, ointments, creams, gels, patches, powders, sprays and lotions may be cited. Application via a stick may prove particularly advantageous for a single sting on a limb, for example. If the mucosa or the eyes are stung, a formulation in the form of a spray or a collyrium, respectively, is preferred.
  • compositions according to the present invention may be dissolved or suspended in a pharmaceutically-acceptable sterile injectable liquid, such as sterile water, sterile organic solvent or a mixture of these two liquids for local administration in a dose of 0.001 mg to 1 mg per venomous hymenoptera sting.
  • a pharmaceutically-acceptable sterile injectable liquid such as sterile water, sterile organic solvent or a mixture of these two liquids for local administration in a dose of 0.001 mg to 1 mg per venomous hymenoptera sting.
  • FIG. 1 Percentage of inhibition of bee venom PLA2 activity as a function of acid concentration as follows:
  • FIG. 1A Linoleic acid (example 1)
  • FIG. 1B Oleic acid (example 1)
  • FIG. 2 Effect of oleic acid and linoleic acid on rat-paw volume increase in an inflammation model as a function of time following bee venom injection (example 2, experiment 1).
  • FIG. 3 Effect of oleic acid and linoleic acid on rat-paw volume increase in an inflammation model as a function of time following bee venom injection (example 2, experiment 2).
  • FIG. 4 Effect of oleic acid and linoleic acid on rat-paw volume increase in an inflammation model as a function of time following bee venom injection (example 2, experiment 3).
  • PLA2 activity is determined by using a radioactive substrate, L-a-dipalmitoyl-[2,9,10(N)-3H-palmitoyl]-phosphatidylcholine. The reaction is carried out in 1 ml of glycine/NaOH buffer, pH 9, containing 2.2 mM deoxycholate, 0.11 ⁇ Ci of dipalmitoyl-PC and 32 mU/ml of bee venom PLA2.
  • the reaction is quenched by adding 0.2 ml of a Triton X-100/EDTA solution, and then the reaction product, radiolabeled palmitic acid, is extracted by a hexane solution containing 0.1% acetic acid and 0.7 g/ml Na 2 SO 4 .
  • the radioactivity of the extract is determined using a liquid scintillation counter. The results represent the mean ⁇ SEM of the CPM values obtained in two independent experiments.
  • FIGS. 1A and 1B illustrate the percentage of inhibition of PLA2 activity (vertical axis) as a function of the concentration of the fatty acid used (horizontal axis).
  • Bee venom (20 ⁇ g/ml in 0.9% NaCl) is incubated at room temperature in the presence or absence of linoleic acid (32 ⁇ M). Thirty minutes after incubation begins, the solutions (25 ⁇ l) are injected subcutaneously in the upper surface of the foot of Sprague-Dawley rats (110-140 g). Edema is measured using a plethysmometer at 5, 10, 15, 20, 30, 60 and 90 minutes following injection. The results represent the mean ⁇ SEM of 5 animals. Statistical comparisons are performed using a t-test, for which the control group is comprised of animals having received venom alone. (*p ⁇ 0.05, ***p ⁇ 0.005) The results are represented in FIG. 2 .
  • the Sprague-Dawley rats (110-140 g) either receive or do not receive, on the top of the foot, an application of topical linoleic acid.
  • Edema is measured using a plethysmometer at 5, 10, 15, 20 and 30 minutes following subcutaneous injection of bee venom in the upper surface of the animal's foot.
  • the results represent the mean+SEM of 20 animals.
  • Statistical comparisons are performed using a t-test, for which the control group is comprised of animals treated with the carrier (acetone).(*p ⁇ 0.05, **p ⁇ 0.01, ***p ⁇ 0.005)
  • the Sprague-Dawley rats (110-140 g) either receive or do not receive, on the top of the foot, an application of topical oleic acid. Edema is measured using a plethysmometer at 5, 10, 15 and 20 minutes following subcutaneous injection of bee venom in the upper surface of the animal's foot. The results ( FIG. 4 ) represent the mean ⁇ SEM of 5 animals. Statistical comparisons are performed using a t-test, for which the control group is comprised of animals treated with the carrier (acetone). (*p ⁇ 0.05)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The invention relates to the use of a fatty acid for preparing a composition for allaying inflammatory reactions due to hypenoptera stings.

Description

  • The present invention relates to the use of a fatty acid for the preparation of a topical composition for allaying inflammatory reactions due to hymenoptera stings.
  • Insects that secrete substances harmful to humans are rather numerous in our part of the world. Between wasps, hornets, bumblebees, ants and honeybees, the risks of being stung are not insignificant. These insects are called hymenoptera. Their sting can cause local or generalized non-allergic reactions as well as local or generalized allergic reactions.
  • Local non-allergic reactions are due to a nonspecific inflammatory reaction. A typical reaction to a hymenoptera sting consists of immediate pain combined with redness, itching and edema in an area several centimeters in diameter. The progression of the reaction is variable. The reaction can last a few hours (three on average) and generally does not last more than one day. Particular types of reactions do exist, however. Stings that lead to non-allergic reactions at specific sites can have dramatic consequences. Stings in the oral cavity, in particular at the back of the throat, can lead to respiratory disorders due to local edema. Finally, stings to the cornea of the eye can cause immediate complications such as an ocular abscess or perforation of the globe. Certain complications may appear later, including cataracts or glaucoma.
  • Generalized non-allergic reactions may be encountered when multiple stings cause severe envenomation. These reactions include digestive disorders with diarrhea and vomiting, a drop in blood pressure occasionally associated with palpitations, sporadic convulsions and an attack on the muscles that can lead to renal failure (in the context of rhabdomyolysis). These reactions generally appear after more than approximately thirty stings.
  • Allergic reactions concern roughly 1% of the population. They can be local, regional, generalized or delayed. They are generally categorized according to severity: local reaction (broader than the normal reaction but limited to a limb), regional reaction (reaction that reaches the joints of the stung limb), generalized reaction (distal skin, respiratory symptoms, Quincke's edema, asthma, digestive symptoms, palpitations), and anaphylactic shock (drop in blood pressure in addition to the symptoms described, spontaneously fatal).
  • The hymenoptera include a number of species including bees, wasps, hornets and ants. Although most hymenoptera stings cause only moderate pain and a limited, temporary reaction, they may be dangerous, even fatal, if multiple stings occur, if they occur in the mouth, in the throat, or to the eye, or if the stung subject has an allergic reaction. The stung subject initially feels a more or less sharp pain depending on the type of insect and the quantity of venom injected. The skin around the sting becomes red and swollen. The subject feels itching that is more or less intense.
  • Recent work has shown that insect venom, in particular bee venom, is a complex substance comprised of a large number of active compounds including histamine, melittin, hyaluronidase and phospholipase A. Sensitivity to these venom proteins may explain some of the reactions described above.
  • The applicant thus has found, surprisingly, that these fatty acids, in particular C12-C24 acids, considerably reduce the inflammatory reaction that follows a hymenoptera sting.
  • Thus, the present invention relates to the use of a fatty acid for preparing a topical or injectable composition for allaying inflammatory reactions due to hymenoptera stings.
  • The fatty acids used in the present invention are preferably natural fatty acids, i.e., capable of being obtained from natural product such as oils, but also synthetic fatty acids that are identical to or are different from natural fatty acids.
  • Moreover, suitable fatty acids may be saturated or unsaturated fatty acids. The salts or the pharmaceutically acceptable derivatives of these fatty acids that are also fatty acids may also be used.
  • Among the fatty acids used within the framework of the present invention, the following may be cited in particular: C12 to C24 acids, lauric (n-dodecanoic) acid, myristic (n-tetradecanoic) acid, palmitic (n-hexadecanoic) acid, stearic (n-octadecanoic) acid, arachidic (n-eicosanoic) acid, behenic (n-docosanoic) acid, lignoceric (n-tetracosanoic) acid, palmitoleic (cis-Δ9-hexadecenoic) acid, oleic (cis-Δ9-octadecenoic) acid, linoleic (cis,cis-Δ9-,Δ12-octadecadienoic) acid, linolenic (all-cis-Δ9-,Δ12-,Δ15-octadecatrienoic) acid, and arachidonic (all-cis-Δ5-,Δ8-,Δ11-,Δ14-eicosatetraenoic) acid.
  • Polyunsaturated fatty acids are preferred, and linoleic acid and oleic acid are particularly active in the use according to the invention.
  • The fatty acids were tested in vitro for their capacity to inhibit the activity of certain pro-inflammatory components of bee venom, and tested in vivo in rat in models of bee venom induced edemas.
  • The results of these tests show that fatty acids can be used to produce compositions for local treatment of inflammation resulting from venomous hymenoptera stings.
  • In the present case, the composition to which the invention relates may also include other active ingredients, notably an anesthetic and/or an antibiotic and/or an anti-allergic or anti-inflammatory substance.
  • The fatty acids can be formulated in any form suitable for topical administration, in combination with suitable excipients, to allow administration of a dose of 0.01 mg to 50 mg per venomous hymenoptera sting. Of course, the dose may vary according to the quantity of venom absorbed, the number of stings or the type of insect.
  • Among the galenical formulations which may be suitable for implementing the invention, ointments, creams, gels, patches, powders, sprays and lotions may be cited. Application via a stick may prove particularly advantageous for a single sting on a limb, for example. If the mucosa or the eyes are stung, a formulation in the form of a spray or a collyrium, respectively, is preferred.
  • In certain cases it will be preferable to administer the composition according to the present invention via local injection. The active substances of the pharmaceutical compositions according to the invention may be dissolved or suspended in a pharmaceutically-acceptable sterile injectable liquid, such as sterile water, sterile organic solvent or a mixture of these two liquids for local administration in a dose of 0.001 mg to 1 mg per venomous hymenoptera sting.
  • The invention will be better understood upon consideration of the examples below which refer to the following figures:
  • FIG. 1: Percentage of inhibition of bee venom PLA2 activity as a function of acid concentration as follows:
  • FIG. 1A: Linoleic acid (example 1)
  • FIG. 1B: Oleic acid (example 1)
  • FIG. 2: Effect of oleic acid and linoleic acid on rat-paw volume increase in an inflammation model as a function of time following bee venom injection (example 2, experiment 1).
  • FIG. 3: Effect of oleic acid and linoleic acid on rat-paw volume increase in an inflammation model as a function of time following bee venom injection (example 2, experiment 2).
  • FIG. 4: Effect of oleic acid and linoleic acid on rat-paw volume increase in an inflammation model as a function of time following bee venom injection (example 2, experiment 3).
    •  EXAMPLE I In vitro inhibiting effects of linoleic acid and oleic acid on bee venom phospholipase A2 (PLA2) activity, a major inflammatory component of said venom.
  • The effect of linoleic acid and oleic acid on PLA2 activity is measured according to the hexane extraction method described by M. Katsumata, G. Gupta, and A. S. Goldman, (1986), Anal. Biochem. 154 (2), 676-681. PLA2 activity is determined by using a radioactive substrate, L-a-dipalmitoyl-[2,9,10(N)-3H-palmitoyl]-phosphatidylcholine. The reaction is carried out in 1 ml of glycine/NaOH buffer, pH 9, containing 2.2 mM deoxycholate, 0.11 μCi of dipalmitoyl-PC and 32 mU/ml of bee venom PLA2. After 20 minutes of incubation, the reaction is quenched by adding 0.2 ml of a Triton X-100/EDTA solution, and then the reaction product, radiolabeled palmitic acid, is extracted by a hexane solution containing 0.1% acetic acid and 0.7 g/ml Na2SO4. The radioactivity of the extract is determined using a liquid scintillation counter. The results represent the mean±SEM of the CPM values obtained in two independent experiments.
  • FIGS. 1A and 1B illustrate the percentage of inhibition of PLA2 activity (vertical axis) as a function of the concentration of the fatty acid used (horizontal axis).
  • These results show that linoleic acid and oleic acid inhibit the enzymatic activity of bee venom PLA2 in a dose-dependent manner.
    • EXAMPLE II
  • Activity of oleic acid and linoleic acid in a rat model of inflammatory edema caused by bee venom (G. A. Rabinovtch, E. C. Sotomayor, C. M. Riera, I. Bianco and S. G. Correa (2000), Eur. J. Immunol. 30, 1331-1339; J. Chen, C. Luo, H. L. Li, and H. S. Chen, (1999), Pain, 83, 67-76).
  • Experiment 1:
  • Bee venom (20 μg/ml in 0.9% NaCl) is incubated at room temperature in the presence or absence of linoleic acid (32 μM). Thirty minutes after incubation begins, the solutions (25 μl) are injected subcutaneously in the upper surface of the foot of Sprague-Dawley rats (110-140 g). Edema is measured using a plethysmometer at 5, 10, 15, 20, 30, 60 and 90 minutes following injection. The results represent the mean±SEM of 5 animals. Statistical comparisons are performed using a t-test, for which the control group is comprised of animals having received venom alone. (*p<0.05, ***p<0.005) The results are represented in FIG. 2.
  • Experiment 2:
  • At 120 and 30 minutes before the injection of bee venom (20 μ0.9% NaCl), the Sprague-Dawley rats (110-140 g) either receive or do not receive, on the top of the foot, an application of topical linoleic acid. Edema is measured using a plethysmometer at 5, 10, 15, 20 and 30 minutes following subcutaneous injection of bee venom in the upper surface of the animal's foot. The results (FIG. 3) represent the mean+SEM of 20 animals. Statistical comparisons are performed using a t-test, for which the control group is comprised of animals treated with the carrier (acetone).(*p<0.05, **p<0.01, ***p<0.005)
  • Experiment 3:
  • At 120 and 30 minutes before the injection of bee venom (20 μg/ml in 0.9% NaCl), the Sprague-Dawley rats (110-140 g) either receive or do not receive, on the top of the foot, an application of topical oleic acid. Edema is measured using a plethysmometer at 5, 10, 15 and 20 minutes following subcutaneous injection of bee venom in the upper surface of the animal's foot. The results (FIG. 4) represent the mean±SEM of 5 animals. Statistical comparisons are performed using a t-test, for which the control group is comprised of animals treated with the carrier (acetone). (*p<0.05)

Claims (10)

1-6. (canceled)
7. A method for allaying an inflammatory reaction due to a hymenoptera sting, comprising:
administering a composition comprising a fatty acid to a subject,
wherein the composition is administered at least one of topically or by injection.
8. The method according to claim 7, wherein the fatty acid comprises a C12-C24 acid.
9. The method according to claim 7, wherein the fatty acid comprises at least one of lauric (n-dodecanoic) acid, myristic (n-tetradecanoic) acid, palmitic (n-hexadecanoic) acid, stearic (n-octadecanoic) acid, arachidic (n-eicosanoic) acid, behenic (n-docosanoic) acid, lignoceric (n-tetracosanoic) acid, palmitoleic (cis-9-hexadecenoic) acid, oleic (cis-Δ9-octadecenoic) acid, linoleic (cis,cis-Δ9-,Δ12-octadecadienoic) acid, linolenic (all-cis-Δ9-,Δ12-,Δ15-octadecatrienoic) acid, or arachidonic (all-cis-Δ5-,Δ8-,Δ11-,Δ14-eicosatetraenoic) acid.
10. The method according to claim 7, wherein the fatty acid is selected from the group consisting of lauric (n-dodecanoic) acid, myristic (n-tetradecanoic) acid, palmitic (n-hexadecanoic) acid, stearic (n-octadecanoic) acid, arachidic (n-eicosanoic) acid, behenic (n-docosanoic) acid, lignoceric (n-tetracosanoic) acid, palmitoleic (cis-Δ9-hexadecenoic) acid, oleic (cis-Δ9-octadecenoic) acid, linoleic (cis,cis-Δ9-,Δ12-octadecadienoic) acid, linolenic (all-cis-Δ9-,Δ12-, Δ15-octadecatrienoic) acid, and arachidonic (all-cis-Δ5-,Δ8 ,Δ11-,Δ14-eicosatetraenoic) acid.
11. The method according to claim 7, wherein the fatty acid comprises at least one of linoleic acid or oleic acid.
12. The method according to claim 7, wherein the fatty acid is selected from the group consisting of linoleic acid and oleic acid.
13. The method according to claim 7, wherein the composition has a form of at least one of an ointment, a cream, a gel, a patch, a powder, a spray, a lotion or a stick.
14. The method according to claim 7, wherein the composition is provided in an injectable form.
15. The method according to claim 7, wherein the composition is applied to a region of tissue close to the sting.
US11/572,437 2004-07-21 2005-07-18 Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings Abandoned US20080096963A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0408070A FR2873293B1 (en) 2004-07-21 2004-07-21 USE OF A FATTY ACID FOR THE PREPARATION OF A TOPIC COMPOSITION FOR THE SATURATION OF INFLAMMATORY REACTIONS DUE TO VENOUS HYMENOPTER PENSIONS
FR0408070 2004-07-21
PCT/FR2005/001826 WO2006021647A1 (en) 2004-07-21 2005-07-18 Use of a fatty acid for preparing a topical composition for allaying inflammatory reactions due to venemous hymenoptera stings

Publications (1)

Publication Number Publication Date
US20080096963A1 true US20080096963A1 (en) 2008-04-24

Family

ID=34948226

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/572,437 Abandoned US20080096963A1 (en) 2004-07-21 2005-07-18 Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings

Country Status (7)

Country Link
US (1) US20080096963A1 (en)
EP (1) EP1768659A1 (en)
AU (1) AU2005276345A1 (en)
CA (1) CA2574345A1 (en)
FR (1) FR2873293B1 (en)
IL (1) IL180814A0 (en)
WO (1) WO2006021647A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20111284A1 (en) * 2011-07-11 2013-01-12 Giovanni Nusca PHARMACEUTICAL COMPOSITION.
WO2017190141A1 (en) 2016-04-29 2017-11-02 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
US10130574B2 (en) * 2015-03-20 2018-11-20 Dow Global Technologies Llc Nitrone inhibition of oxidation of unsaturated fats
US10232048B1 (en) 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
US11413321B2 (en) 2017-12-26 2022-08-16 Hirotaro FUKUOKA Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1913631A (en) * 1929-09-13 1933-06-13 Graves George De Witt Means and method of neutralizing insect and plant poisons
US20040185115A1 (en) * 2002-05-17 2004-09-23 Maurine Pearson Emu oil based methods and compositions for skin ailments

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU729680B2 (en) * 1997-06-13 2001-02-08 Taisho Pharmaceutical Co., Ltd. Aerosol preparation
JP2000159678A (en) * 1998-11-30 2000-06-13 Nof Corp Skin external preparation composition

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1913631A (en) * 1929-09-13 1933-06-13 Graves George De Witt Means and method of neutralizing insect and plant poisons
US20040185115A1 (en) * 2002-05-17 2004-09-23 Maurine Pearson Emu oil based methods and compositions for skin ailments

Cited By (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013007700A1 (en) * 2011-07-11 2013-01-17 Nusca Giovanni Pharmaceutical composition comprising oleic acid, palmitic acid, linoleic acid and linolenic acid
ITMI20111284A1 (en) * 2011-07-11 2013-01-12 Giovanni Nusca PHARMACEUTICAL COMPOSITION.
US10232048B1 (en) 2014-11-18 2019-03-19 Divine Api-Logics, LLC Apitherapy method and composition
US10130574B2 (en) * 2015-03-20 2018-11-20 Dow Global Technologies Llc Nitrone inhibition of oxidation of unsaturated fats
AU2017257185B9 (en) * 2016-04-29 2023-07-06 Ophirex, Inc. Phospholipase A2 inhibitors for immediate treatment of venom toxicity that causes hemolysis, cerebral edema, and acute kidney injury
IL262620B1 (en) * 2016-04-29 2023-10-01 Ophirex Inc Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
JP2019514935A (en) * 2016-04-29 2019-06-06 オフィレックス インコーポレイテッド PLA2 and HMG-COA inhibitors for the treatment of conditions causing hemolysis, brain edema and acute kidney injury
EP3448378A4 (en) * 2016-04-29 2020-04-08 Ophirex, Inc. PLA2 AND HMG-COA INHIBITORS FOR TREATING PATHOLOGICAL CONDITIONS THAT CAUSE HEMOLYSIS, CEREBRAL EDM AND ACUTE KIDNEY DAMAGE
US12383531B2 (en) 2016-04-29 2025-08-12 Ophirex, Inc. PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury
JP2022177020A (en) * 2016-04-29 2022-11-30 オフィレックス インコーポレイテッド PLA2 and HMG-COA inhibitors for the treatment of conditions causing hemolysis, cerebral edema and acute kidney injury
AU2017257185B2 (en) * 2016-04-29 2023-06-22 Ophirex, Inc. Phospholipase A2 inhibitors for immediate treatment of venom toxicity that causes hemolysis, cerebral edema, and acute kidney injury
AU2017257185B8 (en) * 2016-04-29 2023-07-06 Ophirex, Inc. Phospholipase A2 inhibitors for immediate treatment of venom toxicity that causes hemolysis, cerebral edema, and acute kidney injury
WO2017190141A1 (en) 2016-04-29 2017-11-02 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
CN116585306A (en) * 2016-04-29 2023-08-15 奥菲瑞克斯股份有限公司 PLA2 Inhibitors for Immediate Treatment of Hymenopteran Injections and Other Conditions Caused by Histamine Release
CN109562098A (en) * 2016-04-29 2019-04-02 奥菲瑞克斯股份有限公司 PLA2 and HMG-COA inhibitors for the treatment of pathological conditions causing hemolysis, cerebrovascular and acute kidney injury
IL262620B2 (en) * 2016-04-29 2024-02-01 Ophirex Inc Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
JP7542935B2 (en) 2016-04-29 2024-09-02 オフィレックス インコーポレイテッド PLA2 AND HMG-COA INHIBITORS FOR THE TREATMENT OF CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA AND ACUTE KIDNEY INJURY - Patent application
US12343369B2 (en) 2017-12-26 2025-07-01 Hirotaro FUKUOKA Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair
US11413321B2 (en) 2017-12-26 2022-08-16 Hirotaro FUKUOKA Pharmaceutical composition for use in increasing hair, modifying scalp or skin, healing a wound, promoting osteogenesis, or modifying hair

Also Published As

Publication number Publication date
FR2873293B1 (en) 2006-11-17
FR2873293A1 (en) 2006-01-27
AU2005276345A1 (en) 2006-03-02
CA2574345A1 (en) 2006-03-02
IL180814A0 (en) 2007-07-04
EP1768659A1 (en) 2007-04-04
WO2006021647A1 (en) 2006-03-02

Similar Documents

Publication Publication Date Title
RU2468809C2 (en) Andrographis paniculata extract
US20230405126A1 (en) Formulations and uses thereof
US8835410B2 (en) Treatment of eyelid dermatitis
EP1076553A2 (en) Pharmaceutical, hygienic and/or cosmetic compositions containing sea water and uses
JP7153429B2 (en) Active oxygen scavenging agent
WO2008148572A1 (en) Anti-inflammatory active ingredient combination for the treatment of diseases of the skin and mucous membranes
US11446277B2 (en) Penetrating pain relief cream
EP2164481A2 (en) Medicament comprising an active substance combination containing pantothenic acid or the derivatives thereof for the treatment of allergy symptoms
US20170189466A1 (en) Compositions for the Treatment of Dermatological Conditions, Disorders or Diseases
US20130273019A1 (en) Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation
EP1521588A2 (en) Use of alanyl-aminopeptidase inhibitors and pharmaceutical compositions containing said inhibitors
US20080096963A1 (en) Use Of A Fatty Acid For Preparing A Topical Composition For Allaying Inflammatory Reaction Due To Vennemous Hymenoptera Strings
CN102716395A (en) Traditional Chinese medicine spray for treating skin diseases
US11590211B2 (en) Systems for treating dermal inflammatory conditions
KR20180054821A (en) Triterpenoid-containing composition
EP3675814A1 (en) Composition for topical treatment of non-microorganism-caused inflammatory skin and mucous-membrane diseases
DE102020131716A1 (en) New therapy concept for the treatment of corona infections, especially COVID-19 infections
EP4216944B1 (en) New therapy concept for the treatment of corona infections, more particularly covid-19 infections
RU2426540C1 (en) Anti-inflammatory and anti-allergic medication and based on it pharmaceutical composition
US20130287859A1 (en) Method for treating prupritus with cartilage extract
TWI903311B (en) Local pharmaceutical composition, preparation method and use in medicine thereof
JPH0971539A (en) Topical antipruritic
JP2024128672A (en) Facial skin condition improver
EP1891940A1 (en) Intrasynovial formulations of stanozolol
Roze Cyclosporine in canine ophthalmology.

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION